WASHINGTON DC—Laboratory evidence that giving patients intermittent rather than continuous treatment with cancer drugs could help them overcome drug resistance in cancers such as melanoma was presente
WASHINGTON DC—Laboratory evidence that giving patients intermittent rather than continuous treatment with cancer drugs could help them overcome drug resistance in cancers such as melanoma was presented at the American Association for Cancer Research 2013 meeting. Dr Darrin Stuart from the Novartis Institutes for Biomedical Research in Emeryville, California, presented research findings on mice treated with vemurafenib. He told Peter Goodwin why he thought this should prompt clinicians to look carefully at drug scheduling and consider intermittent therapy as a means of overcoming resistance in patients with cancer.